Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2806
Abstract: In closely monitored randomized controlled trials (RCTs), newer P2Y12 agents (ticagrelor and prasugrel) reduced cardiovascular outcomes compared with clopidogrel following percutaneous coronary intervention (PCI) in acute coronary syndrome. However, these RCTs indicated a higher bleeding… read more here.
Keywords: p2y12; major bleeding; prasugrel; clopidogrel ... See more keywords
Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome
Sign Up to like & getrecommendations! Published in 2017 at "Heart and Vessels"
DOI: 10.1007/s00380-017-1016-1
Abstract: Prasugrel is often replaced with clopidogrel after a certain period of time following coronary stenting. However, the time course of platelet aggregation during this replacement is unknown. We performed a prospective, single-arm study to monitor… read more here.
Keywords: prasugrel; time course; time; acute coronary ... See more keywords
One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-017-0255-y
Abstract: BackgroundNo direct comparisons of ticagrelor and prasugrel with 1-year clinical follow-up have been reported.ObjectivesOur objective was to compare 1-year clinical outcomes among patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) and… read more here.
Keywords: prasugrel; ticagrelor; study; prasugrel ticagrelor ... See more keywords
Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel.
Sign Up to like & getrecommendations! Published in 2018 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2018.08.044
Abstract: BACKGROUND AND AIMS Increased platelet reactivity (PR) associated with variable degree of coronary microvascular impairment has been reported in patients on clopidogrel after elective percutaneous coronary intervention (PCI). Prasugrel provides more potent platelet inhibition than… read more here.
Keywords: prasugrel; clopidogrel; microvascular impairment; pci ... See more keywords
Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial.
Sign Up to like & getrecommendations! Published in 2018 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2017.12.055
Abstract: BACKGROUND Clopidogrel is used to pretreat patients with non-ST elevation acute coronary syndromes (NSTE-ACS), but prasugrel provides better platelet inhibition with improved outcome. However, switching from clopidogrel at the time of percutaneous coronary intervention (PCI)… read more here.
Keywords: switching clopidogrel; prasugrel; clopidogrel; platelet inhibition ... See more keywords
Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.01.027
Abstract: Ticagrelor is a nonthienopyridine direct and reversible P2Y12 platelet receptor antagonist, and unlike prasugrel or clopidogrel inhibits, at least partially, the sodium-independent equilibrative nucleoside transporter 1 [(1)][1]. This ticagrelor-mediated off-target effect has potential to improve read more here.
Keywords: prasugrel; clopidogrel steady; prasugrel clopidogrel; ticagrelor prasugrel ... See more keywords
Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of cardiology"
DOI: 10.1016/j.jjcc.2017.05.003
Abstract: BACKGROUND Although there have been several reports that prasugrel can improve clinical outcomes, the efficacy and safety of prasugrel is unknown in Korean patients with acute myocardial infarction (AMI) undergoing successful revascularization. METHODS A total… read more here.
Keywords: prasugrel; myocardial infarction; undergoing successful; acute myocardial ... See more keywords
The Degradation Chemistry of Prasugrel Hydrochloride: Part 1-Drug Substance.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of pharmaceutical sciences"
DOI: 10.1016/j.xphs.2019.04.008
Abstract: Prasugrel hydrochloride is the active ingredient in Effient™, a thienopyridine platelet inhibitor. An extensive study of the degradation chemistry of prasugrel hydrochloride (LY640315 hydrochloride) has been carried out on the drug substance (part I) and… read more here.
Keywords: degradation; drug substance; prasugrel; chemistry ... See more keywords
COMPARISON OF BLEEDING RATES AND CLINICAL OUTCOMES BETWEEN TICAGRELOR AND PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A PROPENSITY SCORE-MATCHED ANALYSIS
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)34404-2
Abstract: Background: In acute coronary syndrome (ACS) patients following percutaneous coronary intervention (PCI), ticagrelor or prasugrel are increasingly used, but limited data are available on the safety and efficacy of ticagrelor vs. prasugrel use in real… read more here.
Keywords: prasugrel; ticagrelor prasugrel; acute coronary; percutaneous coronary ... See more keywords
Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-73871-x
Abstract: Whether newer P2Y12 inhibitors are more efficacious and safer than clopidogrel and whether there is a superior one remain uncertain. We compared the effect of P2Y12 inhibitors on clinical outcomes in patients with acute coronary… read more here.
Keywords: prasugrel; clopidogrel; ticagrelor; acute coronary ... See more keywords
Solid self nano-emulsifying system for the enhancement of dissolution and bioavailability of Prasugrel HCl: in vitro and in vivo studies
Sign Up to like & getrecommendations! Published in 2021 at "Pharmaceutical Development and Technology"
DOI: 10.1080/10837450.2021.1973495
Abstract: Abstract Prasugrel Hydrochloride (PHCl) is an antiplatelet drug. It is a class II drug with variable bioavailability. The objective of this work was to enhance the solubility and hence the bioavailability and efficacy of PHCl.… read more here.
Keywords: prasugrel; bioavailability; drug; self nano ... See more keywords